Geode Capital Management, LLC Lineage Cell Therapeutics, Inc. Transaction History
Geode Capital Management, LLC
- $1.24 Trillion
- Q1 2025
A detailed history of Geode Capital Management, LLC transactions in Lineage Cell Therapeutics, Inc. stock. As of the latest transaction made, Geode Capital Management, LLC holds 4,485,586 shares of LCTX stock, worth $4.22 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
4,485,586
Previous 3,690,486
21.54%
Holding current value
$4.22 Million
Previous $1.85 Million
9.38%
% of portfolio
0.0%
Previous 0.0%
Shares
22 transactions
Others Institutions Holding LCTX
# of Institutions
139Shares Held
108MCall Options Held
8KPut Options Held
3K-
Broadwood Capital Inc New York, NY49.6MShares$46.6 Million1.86% of portfolio
-
Black Rock Inc. New York, NY9.56MShares$8.99 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.92MShares$8.38 Million0.0% of portfolio
-
Defender Capital, Llc.6.31MShares$5.93 Million1.19% of portfolio
-
Raffles Associates LP New York, NY5.64MShares$5.3 Million3.45% of portfolio
About Lineage Cell Therapeutics, Inc.
- Ticker LCTX
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 169,755,008
- Market Cap $160M
- Description
- Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-re...